百利天恒(688506.SH)再度拉升涨超6%,报188元续刷上市高价,4月底以来累计飙升55%,总市值达742亿元。消息上,公司日前公告,“BL-B01D1+PD-1单抗±化疗”治疗多种晚期实体瘤获得7个II期临床试验批准通知书。此前,多款创新药被NMPA纳入突破性治疗药物品种,涉及信达生物、百利天恒等药企。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.